After surgery for suspected lung cancer, benign disease diagnosis rates varied widely by state.
And the reasons for these variations could inform health policy and clinical guidelines for lung cancer screening. This is according to a researcher who presented the data at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.
"Given the results of the National Lung Screening Trial (NLST), which demonstrated that low-dose computed tomography (CT) reduces lung cancer mortality, and the support for screening healthy, high-risk individuals with low-dose CT by clinical and patient advocacy groups, we will likely see screening for lung cancer in our near future," said Stephen A. Deppen, a doctoral candidate in epidemiology and database analyst at Vanderbilt University in Nashville, Tenn.
"It was not known whether the prevalence of benign disease diagnosis after lung resection for suspected lung cancer is uniform across the United States," said Deppen. "If prevalence differs by state or region of the country, then a national lung cancer screening program may have varying results."
He and his colleagues, therefore, set out to determine the prevalence of benign disease diagnosis rates by state.
Using the Medicare Provider Analysis and Review (MedPAR) Hospital National Limited Data Set from 2009, Deppen and colleagues evaluated medical data from 25,362 patients who underwent lung surgery for known or suspected lung cancer.
They found that 2,312 patients (9.1 percent) had a benign disease diagnosis after surgery. About 2.3 percent of all patients died in the hospital after the procedure. For those who were found not to have lung cancer, the mortality rate was 2.1 percent.
In addition, there was a wide variation among states in the prevalence of benign disease diagnosis, from 1.2 percent in Vermont to 25 percent in Hawaii.
"States with a higher rate of false positives and higher benign disease prevalence may observe poorer performance of a screening program for lung cancer," Deppen said. "The benefit of screening for lung cancer is finding early-stage disease and reducing mortality from lung cancer. Lung surgery is major surgery and has a much higher risk for death and complications compared with diagnostic operations for other cancers, such as breast and prostate cancer. So, more surgeries for benign disease will result in more deaths and harm from the diagnostic process and will reduce the benefit that was observed in the original NLST."